Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153-Reference-Cited by-同舟云学术

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

Published:2018-02-13 Issue:4 Volume:81 Page:679-686
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Waterhouse David,Horn Leora,Reynolds Craig,Spigel David,Chandler Jason,Mekhail Tarek,Mohamed Mohamed,Creelan Ben,Blankstein Kenneth B.,Nikolinakos Petros,McCleod Michael J.,Li Ang,Oukessou Abderrahim,Agrawal Shruti,Aanur Nivedita

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3527-6/fulltext.html

Reference18 articles.

1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643

2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627

3. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–2012. https://doi.org/10.1200/JCO.2014.58.3708

4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082

5. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, CheckMate 025 Investigators et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813 https://doi.org/10.1056/NEJMoa1510665

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative transcriptome analysis reveals the molecular events underlying impaired T-cell responses in EGFR-mutant lung cancer;Scientific Reports;2024-08-07

2. Management of infusion-related reactions in cancer therapy: strategies and challenges;ESMO Open;2024-03

3. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

4. Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

5. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm;Clinical Pharmacology & Therapeutics;2023-05-11